Denali Therapeutics (DNLI) Non-Current Deffered Revenue (2018 - 2022)

Denali Therapeutics (DNLI) has 5 years of Non-Current Deffered Revenue data on file, last reported at $479000.0 in Q4 2022.

• Quarterly Non-Current Deffered Revenue fell 85.9% year-over-year to $479000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $479000.0 (down 85.9% YoY) and the FY2022 annual result came in at $479000.0, down 85.9% from the prior year.
• Non-Current Deffered Revenue eased to $479000.0 in Q4 2022 per DNLI's latest filing, from $3.4 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $49.6 million in Q2 2018 and bottomed at $479000.0 in Q4 2022.
• The 5-year median for Non-Current Deffered Revenue is $24.5 million (2018), against an average of $24.6 million.
• The widest annual swing landed in 2019, when Non-Current Deffered Revenue surged 641.23%; it then tumbled 89.15% in 2022.
• Tracing DNLI's Non-Current Deffered Revenue over 5 years: stood at $24.5 million in 2018, then jumped by 78.35% to $43.8 million in 2019, then plunged by 46.69% to $23.3 million in 2020, then plunged by 85.43% to $3.4 million in 2021, then sank by 85.9% to $479000.0 in 2022.
• Per Business Quant, the three latest DNLI Non-Current Deffered Revenue figures stand at $479000.0 (Q4 2022), $3.4 million (Q2 2022), and $3.4 million (Q1 2022).

Peer Comparison